Spyre Therapeutics Net Worth
Spyre Therapeutics Net Worth Breakdown | SYRE |
Spyre Therapeutics Net Worth Analysis
Spyre Therapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Spyre Therapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Spyre Therapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Spyre Therapeutics' net worth analysis. One common approach is to calculate Spyre Therapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Spyre Therapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Spyre Therapeutics' net worth. This approach calculates the present value of Spyre Therapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Spyre Therapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Spyre Therapeutics' net worth. This involves comparing Spyre Therapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Spyre Therapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Spyre Therapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Spyre Therapeutics' net worth research are outlined below:
| Spyre Therapeutics generated a negative expected return over the last 90 days | |
| Spyre Therapeutics has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 886 K. Net Loss for the year was (338.79 M) with loss before overhead, payroll, taxes, and interest of (84.05 M). | |
| Spyre Therapeutics generates negative cash flow from operations | |
| Spyre Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Over 88.0% of the company shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Spyre Therapeutics Shares Up 9.4 percent Time to Buy |
Spyre Therapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Spyre Therapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Spyre Therapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 7th of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 7th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Spyre Therapeutics Target Price Consensus
Spyre target price is determined by taking all analyst projections and averaging them out. There is no one specific way to measure analysts' performance other than comparing it to past results via a very sophisticated attribution analysis. Spyre Therapeutics' target price projections below should be used in combination with other traditional price prediction techniques such as stock price forecasting, investor sentiment analysis, technical analysis, earnings estimate, and various momentum models.
| 11 | Strong Buy |
Most Spyre analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to help potential investors understand Spyre stock's fair price compared to its market value. Analysts arrive at stock ratings after researching the public financial statements of Spyre Therapeutics, talking to its executives and customers, or listening to those companies' conference calls.
Macroaxis Advice Exposure ValuationSpyre Therapeutics Target Price Projection
Spyre Therapeutics' current and average target prices are 22.27 and 58.62, respectively. The current price of Spyre Therapeutics is the price at which Spyre Therapeutics is currently trading. On the other hand, Spyre Therapeutics' target price is what analysts think the stock is worth or could sell for in the future. The more significant the discrepancy between the two prices, the more it stimulates investors to act.Current Price
Spyre Therapeutics Market Quote on 31st of January 2025
Target Price
Analyst Consensus On Spyre Therapeutics Target Price
Follow Spyre Therapeutics' market capitalization trends
The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.32 B.Market Cap |
|
Project Spyre Therapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.89) | (0.94) | |
| Return On Capital Employed | (0.70) | (0.74) | |
| Return On Assets | (0.89) | (0.94) | |
| Return On Equity | (1.66) | (1.74) |
When accessing Spyre Therapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Spyre Therapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Spyre Therapeutics' profitability and make more informed investment decisions.
Please note, the presentation of Spyre Therapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Spyre Therapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Spyre Therapeutics' management manipulating its earnings.
Evaluate Spyre Therapeutics' management efficiency
Spyre Therapeutics has return on total asset (ROA) of (0.3881) % which means that it has lost $0.3881 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.9162) %, meaning that it created substantial loss on money invested by shareholders. Spyre Therapeutics' management efficiency ratios could be used to measure how well Spyre Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of January 31, 2025, Return On Tangible Assets is expected to decline to -0.94. In addition to that, Return On Capital Employed is expected to decline to -0.74. At present, Spyre Therapeutics' Other Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Assets is expected to grow to about 412.4 M, whereas Non Currrent Assets Other are forecasted to decline to about 282.7 K.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 28.83 | 27.39 | |
| Tangible Book Value Per Share | 28.83 | 27.39 | |
| Enterprise Value Over EBITDA | (0.38) | (0.40) | |
| Price Book Value Ratio | 0.99 | 0.94 | |
| Enterprise Value Multiple | (0.38) | (0.40) | |
| Price Fair Value | 0.99 | 0.94 | |
| Enterprise Value | 48.3 M | 80.7 M |
The strategic initiatives led by Spyre Therapeutics' management are central to its market success. By analyzing these initiatives, we provide a clear picture of the stock's growth prospects.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Spyre Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Spyre Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Spyre Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Spyre Therapeutics Corporate Filings
F4 | 17th of January 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
8K | 13th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 19th of November 2024 Other Reports | ViewVerify | |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
Spyre Therapeutics Earnings Estimation Breakdown
The calculation of Spyre Therapeutics' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Spyre Therapeutics is estimated to be -1.08375 with the future projection ranging from a low of -1.1375 to a high of -0.9925. Please be aware that this consensus of annual earnings estimates for Spyre Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-1.14 Lowest | Expected EPS | -0.99 Highest |
Spyre Therapeutics Earnings Projection Consensus
Suppose the current estimates of Spyre Therapeutics' value are higher than the current market price of the Spyre Therapeutics stock. In this case, investors may conclude that Spyre Therapeutics is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Spyre Therapeutics' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2024 | Current EPS (TTM) | |
| 10 | 66.65% | -1.36 | -1.08375 | -37.9 |
Spyre Therapeutics Earnings per Share Projection vs Actual
Actual Earning per Share of Spyre Therapeutics refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Spyre Therapeutics predict the company's earnings will be in the future. The higher the earnings per share of Spyre Therapeutics, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Spyre Therapeutics Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Spyre Therapeutics, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Spyre Therapeutics should always be considered in relation to other companies to make a more educated investment decision.Spyre Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Spyre Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2024-11-07 | 2024-09-30 | -0.82 | -1.36 | -0.54 | 65 | ||
2024-08-07 | 2024-06-30 | -0.95 | -0.86 | 0.09 | 9 | ||
2024-05-09 | 2024-03-31 | -1.17 | -1.2 | -0.03 | 2 | ||
2024-02-29 | 2023-12-31 | -0.78 | -4.05 | -3.27 | 419 | ||
2023-11-09 | 2023-09-30 | -0.84 | -9.34 | -8.5 | 1011 | ||
2023-08-11 | 2023-06-30 | -3.48 | -56.25 | -52.77 | 1516 | ||
2023-05-11 | 2023-03-31 | -0.18 | -4.55 | -4.37 | 2427 | ||
2023-03-02 | 2022-12-31 | -0.2283 | -5.0 | -4.7717 | 2090 | ||
2022-11-03 | 2022-09-30 | -0.25 | -4.33 | -4.08 | 1632 | ||
2022-08-04 | 2022-06-30 | -0.3178 | -6.75 | -6.4322 | 2023 | ||
2022-05-05 | 2022-03-31 | -0.3414 | -9.25 | -8.9086 | 2609 | ||
2022-03-08 | 2021-12-31 | -0.2875 | -7.75 | -7.4625 | 2595 | ||
2021-11-04 | 2021-09-30 | -0.2792 | -7.75 | -7.4708 | 2675 | ||
2021-08-05 | 2021-06-30 | -0.1644 | -2.5 | -2.3356 | 1420 | ||
2021-05-10 | 2021-03-31 | -0.2286 | -7.0 | -6.7714 | 2962 | ||
2021-03-18 | 2020-12-31 | -0.3429 | -8.75 | -8.4071 | 2451 | ||
2020-11-05 | 2020-09-30 | -0.3917 | -7.25 | -6.8583 | 1750 | ||
2020-08-10 | 2020-06-30 | -0.43 | -10.0 | -9.57 | 2225 | ||
2020-05-07 | 2020-03-31 | -0.65 | -14.25 | -13.6 | 2092 | ||
2020-02-24 | 2019-12-31 | -0.67 | -16.25 | -15.58 | 2325 | ||
2019-11-06 | 2019-09-30 | -0.54 | -16.5 | -15.96 | 2955 | ||
2019-08-06 | 2019-06-30 | -0.48 | -13.75 | -13.27 | 2764 | ||
2019-05-07 | 2019-03-31 | -0.55 | -14.75 | -14.2 | 2581 | ||
2019-03-07 | 2018-12-31 | -0.37 | -15.5 | -15.13 | 4089 | ||
2018-11-08 | 2018-09-30 | -0.44 | -13.5 | -13.06 | 2968 | ||
2018-08-09 | 2018-06-30 | -0.36 | -11.5 | -11.14 | 3094 | ||
2018-05-08 | 2018-03-31 | -0.44 | -12.25 | -11.81 | 2684 | ||
2018-03-13 | 2017-12-31 | -0.53 | -9.75 | -9.22 | 1739 | ||
2017-11-08 | 2017-09-30 | -0.55 | -0.48 | 0.07 | 12 | ||
2017-08-08 | 2017-06-30 | -0.48 | -0.47 | 0.01 | 2 | ||
2017-05-18 | 2017-03-31 | -0.47 | -0.47 | 0.0 | 0 | ||
2017-03-08 | 2016-12-31 | -0.46 | -0.56 | -0.1 | 21 | ||
2016-11-08 | 2016-09-30 | -0.55 | -0.47 | 0.08 | 14 | ||
2016-08-18 | 2016-06-30 | -0.43 | -0.46 | -0.03 | 6 |
Spyre Therapeutics Corporate Management
| James JD | Consultant | Profile | |
| Janet MBA | Senior Operations | Profile | |
| Eric McIntyre | Vice Relations | Profile | |
| Deanna MD | Senior Development | Profile | |
| CFE CPA | Vice Controller | Profile | |
| Justin LaFountaine | Senior Development | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Spyre Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. For information on how to trade Spyre Stock refer to our How to Trade Spyre Stock guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spyre Therapeutics. If investors know Spyre will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Spyre Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Spyre Therapeutics is measured differently than its book value, which is the value of Spyre that is recorded on the company's balance sheet. Investors also form their own opinion of Spyre Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Spyre Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Spyre Therapeutics' market value can be influenced by many factors that don't directly affect Spyre Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Spyre Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spyre Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Spyre Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.